Dr. Jordan goes to DC: Father of tamoxifen joins Lombardi

Publication
Article
Oncology NEWS Today BlogOncology NEWS Today Blog Vol 18 No 5
Volume 18
Issue 5

V. Craig Jordan, OBE, PhD, DSc, will become the scientific director for the cancer center and vice chairman of the department of oncology at Georgetown University Medical Center and the Lombardi Comprehensive Cancer Center.

V. Craig Jordan, OBE, PhD, DSc, will become the scientific director for the cancer center and vice chairman of the department of oncology at Georgetown University Medical Center and the Lombardi Comprehensive Cancer Center.

Dr. Jordan will take up his post at the Washington, DC-based institutions in July. He will also occupy an endowed chair. Dr. Jordan currently serves as vice president and scientific director for the medical sciences at Fox Chase Cancer Center in Philadelphia, where he holds the Alfred G. Knudson Jr., MD, PhD, Chair in Cancer Research. Dr. Jordan is also an adjunct professor of cancer biology at the University of Pennsylvania and a visiting professor of molecular medicine at the University of Leeds in England.

To learn more about Dr. Jordan’s life and career in “Father of tamoxifen a Brit to the core,” May 2008, visit www.cancernetwork.com

Recent Videos
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
Related Content